SCHEMBL25840214

SCHEMBL25840214

COc1cncc2cc(Br)ccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.40
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
NQO2 P16083 1/20 0.39
RXFP1 Q9HBX9 3/20 0.39
CYP19A1 P11511 1/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
LMNA P02545 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
APAF1 O14727 1/20 0.38
TDP2 O95551 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PDE10A Q9Y233 3/20 0.38
ALPL P05186 1/20 0.37
SLC2A1 P11166 1/20 0.37
GAK O14976 1/20 0.37
ALDH1A1 P00352 1/20 0.37
PRNP P04156 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30517018 1.00 POLB (0.40) POLBIDO1TDO2NQO2RXFP1
SCHEMBL4729352 0.86 IDO1 (0.42) POLBIDO1TDO2CYP19A1CYP11B1
SCHEMBL27983652 0.79 PDE10A (0.43) CYP19A1CYP11B1CYP11B2SMN1; SMN2PDE10A
SCHEMBL13728481 0.79 PDE10A (0.43) IDO1TDO2CYP11B1CYP11B2PDE10A
SCHEMBL25301880 0.78 ALPL (0.40) ALPLMAOA
SCHEMBL28531631 0.77 MAOA (0.46) NQO2RXFP1CYP19A1CYP11B1CYP11B2
SCHEMBL30804197 0.76 NCEH1 (0.43) POLBLMNAL3MBTL1ALDH1A1MAPT
SCHEMBL30099343 0.75 NOS1 (0.39) CYP11B1CYP11B2ALDH1A1MAPT
SCHEMBL5497704 0.75 NOS1 (0.39) CYP11B1CYP11B2ALDH1A1MAPT
SCHEMBL6312903 0.74 KDM4E (0.51) POLBNQO2RXFP1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059196-A1 TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2025-02-20 US disclosed
EP-4458819-A1 TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-11-06 EP disclosed
WO-2023125877-A1 TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 上海翰森生物医药科技有限公司 2023-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059196-A1 TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF WEE1, CYP51A1, WEE2 POLB 2864/4885IDO1 123/4885TDO2 949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.